Literature DB >> 4704495

Ureteric stricture with analgesic nephropathy.

G A MacGregor, N F Jones, M A Barraclough, A J Wing, W I Cranston.   

Abstract

Three patients with analgesic nephropathy are reported who, in addition to the accepted features of this syndrome, had dilatation of one or both upper urinary tracts due to ureteric or periureteric fibrosis without intraluminal obstruction. We attribute this lesion to analgesic abuse and suggest that any patient with unexplained ureteric fibrosis should be questioned about analgesic consumption. This association also suggests a possible role for analgesic abuse in the pathogenesis of retroperitoneal fibrosis.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4704495      PMCID: PMC1589164          DOI: 10.1136/bmj.2.5861.271

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  2 in total

1.  Surgical management of renal papillary necrosis.

Authors:  W F Hendry; A R Harrison; F R Kilpatrick
Journal:  Proc R Soc Med       Date:  1972-11

2.  Malignant retroperitoneal fibrosis.

Authors:  A J Webb; P Dawson-Edwards
Journal:  Br J Surg       Date:  1967-06       Impact factor: 6.939

  2 in total
  5 in total

1.  Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology.

Authors:  C Alberti
Journal:  G Chir       Date:  2015 Jul-Aug

Review 2.  Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics.

Authors:  L F Prescott
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

3.  Drugs associated with retroperitoneal fibrosis.

Authors:  R L Ristagno
Journal:  West J Med       Date:  1981-08

Review 4.  Effects of non-narcotic analgesics on the kidney.

Authors:  P Kincaid-Smith
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 5.  Drug-induced renal disease.

Authors:  J R Curtis
Journal:  Drugs       Date:  1979-11       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.